Last reviewed · How we verify
AD-221
AD-221 is a small molecule inhibitor of the PI3K delta subunit.
AD-221 is a small molecule inhibitor of the PI3K delta subunit. Used for Relapsing multiple sclerosis.
At a glance
| Generic name | AD-221 |
|---|---|
| Sponsor | Addpharma Inc. |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Small molecule |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the PI3K delta subunit, AD-221 reduces the activity of B cells, which are a type of immune cell involved in the development of certain autoimmune diseases. This can help to reduce inflammation and slow disease progression.
Approved indications
- Relapsing multiple sclerosis
Common side effects
- Nausea
- Diarrhea
- Headache
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A (PHASE3)
- A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AD-221 CI brief — competitive landscape report
- AD-221 updates RSS · CI watch RSS
- Addpharma Inc. portfolio CI